Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Nerdwallet Inc (NRDS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Nerdwallet Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B), while Nerdwallet Inc trades at $9.55 (market cap $616.22M). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 14.4× Nerdwallet Inc's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Nerdwallet Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Nerdwallet Inc for 45 Days on average.
| KYMR | NRDS | |
|---|---|---|
Market Cap | $8.87B | $616.22M |
Volume | 779,107 | 640,272 |
Sector | Health | Media |
52-Week High | $127.31 | $15.93 |
52-Week Low | $55.80 | $7.58 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $8.26B | $530.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
NRDS trades at $9.55, down 2.75% today, but maintains strong fundamentals with a P/E of 10.71 and P/S of 0.8, indicating potential undervaluation. The company has shown consistent revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive since 2024. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 beat estimates. Technical indicators show a bullish trend with strong moving average signals, though RSI levels suggest potential overbought conditions.
The outlook for NRDS remains positive with analyst consensus at 66.7% buy ratings and projected 27.9% upside potential. Strong profitability metrics include 93.5% gross margins and 18.16% ROE. Key risks include competitive pressures in financial guidance markets and reliance on organic search traffic. The company's improving cash flow from operations ($132M in 2025) supports continued growth initiatives in personal loans and deposit accounts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →
